Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?

被引:75
|
作者
Abdulameer, Shaymaa Abdalwahed [1 ]
Sulaiman, Syed Azhar Syed [1 ]
Hassali, Mohamed Azmi Ahmad [1 ]
Subramaniam, Karuppiah [2 ]
Sahib, Mohanad Naji [1 ]
机构
[1] Univ Sains Malaysia, Sch Pharmaceut Sci, Minden 11800, Penang, Malaysia
[2] Penang Gen Hosp, Diabet Outpatient Clin, George Town, Malaysia
来源
关键词
bone; diabetes; osteopenia; osteoporosis; skeletal; BONE-MINERAL DENSITY; BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; DIFFERENT SKELETAL SITES; GLYCATION END-PRODUCTS; HIP FRACTURE RISK; POSTMENOPAUSAL WOMEN; US ADULTS; OLDER WOMEN; ELDERLY-WOMEN;
D O I
10.2147/PPA.S32745
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is a pandemic and chronic metabolic disorder with substantial morbidity and mortality. In addition, osteoporosis (OP) is a silent disease with a harmful impact on morbidity and mortality. Therefore, this systematic review focuses on the relationship between OP and type 2 diabetes mellitus (T2DM). Systematic reviews of full-length articles published in English from January 1950 to October 2010 were identified in PubMed and other available electronic databases on the Universiti Sains Malaysia Library Database. The following keywords were used for the search: T2DM, OP, bone mass, skeletal. Studies of more than 50 patients with T2DM were included. Forty-seven studies were identified. The majority of articles (26) showed increased bone mineral density (BMD), while 13 articles revealed decreased BMD; moreover, eight articles revealed normal or no difference in bone mass. There were conflicting results concerning the influence of T2DM on BMD in association with gender, glycemic control, and body mass index. However, patients with T2DM display an increased fracture risk despite a higher BMD, which is mainly attributable to the increased risk of falling. As a conclusion, screening, identification, and prevention of potential risk factors for OP in T2DM patients are crucial and important in terms of preserving a good quality of life in diabetic patients and decreasing the risk of fracture. Patients with T2DM may additionally benefit from early visual assessment, regular exercise to improve muscle strength and balance, and specific measures for preventing falls. Patient education about an adequate calcium and vitamin D intake and regular exercise is important for improving muscle strength and balance. Furthermore, adequate glycemic control and the prevention of diabetic complications are the starting point of therapy in diabetic patients.
引用
收藏
页码:435 / 448
页数:14
相关论文
共 50 条
  • [41] Health inequalities among Latinos: What do we know and what can we do?
    Stone, Lisa Cacari
    Balderrama, C. H. Hank
    HEALTH & SOCIAL WORK, 2008, 33 (01) : 3 - 7
  • [42] Health inequalities and the health of the poor: What do we know? What can we do?
    Gwatkin, DR
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2000, 78 (01) : 3 - 18
  • [43] The cancer-obesity connection: what do we know and what can we do?
    Elio Riboli
    BMC Biology, 12
  • [44] Mental health among clinicians: what do we know and what can we do?
    Mittal Patel
    Steven Swift
    Alex Digesu
    International Urogynecology Journal, 2021, 32 : 1055 - 1059
  • [45] Disparities in educational opportunities and outcomes: What do we know and what can we do?
    Maruyama, G
    JOURNAL OF SOCIAL ISSUES, 2003, 59 (03) : 653 - 676
  • [46] The global child labor problem: What do we know and what can we do?
    Basu, K
    Tzannatos, Z
    WORLD BANK ECONOMIC REVIEW, 2003, 17 (02): : 147 - 173
  • [47] The cancer-obesity connection: what do we know and what can we do?
    Riboli, Elio
    BMC BIOLOGY, 2014, 12
  • [48] Tumour budding in colorectal cancer: what do we know and what can we do?
    Linde De Smedt
    Sofie Palmans
    Xavier Sagaert
    Virchows Archiv, 2016, 468 : 397 - 408
  • [49] Tumour budding in colorectal cancer: what do we know and what can we do?
    De Smedt, Linde
    Palmans, Sofie
    Sagaert, Xavier
    VIRCHOWS ARCHIV, 2016, 468 (04) : 397 - 408
  • [50] BRCA1: What do we know? What do we think we know? What do we really need to know?
    Buller, RE
    GYNECOLOGIC ONCOLOGY, 2000, 76 (03) : 291 - 293